References
- Austin M. A. Plasma triglyceride and coronary heart disease. Arteriosclerosis and Thrombosis 1991; 11: 2–14
- Boyle G. W., McKillop D., Phillips P. J., Harding J. R., Pickford R., McCormick A. D. Metabolism of Casodex in laboratory animals. Xenobiotica 1993; 23: 781–798
- Castelli W. P. The triglyceride issue: a view from Framingham. American Heart Journal 1986; 112: 432–437
- Fontbone A., Eschwege E., Cambien F., Richard J. L., Ducimetiere P., Thibult N., Warnet J. M., Claude J. R., Rosselin G. E. Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32: 300–304
- Goto K., Morioka Y., Kanamitsu S., Tsutsumi K., Naito S. Species specificity of metabolism of antillipidaemic agent NO-1886. Presented at 10th Annual Meeting of the Japanese Society for the Study of Xenobiotics, OomiyaJapan, November, 7–91995
- Imai Y., Ito A., Sato R. Evidence for biochemically different types of vesicles in the hepatic microsomal fraction. Journal of Biochemistry 1966; 60: 417–428
- Lapidus L., Bengtsson C., Lindquist O., Sigurdsson J. A., Rybo E. Triglyceride: main lipid risk factor for cardiovascular disease in woman. Acta Medica Scandinavica 1985; 217: 481–489
- Nicholls P. J., Ross M. S. F., Luscombe D. K. Metabolism of beclamide, N-benzyl-3-chloropropionamide, in man. Xenobiotica 1979; 9: 129–140
- Remmer H., Schenkman J. B., Estabrook R. W., Sasame H., Gillette J. R., Narasimhulu S., Cooper D. Y., Rosenthal O. Drug interaction with hepatic microsomal cytochrome. Molecular Pharmacology 1966; 2: 187–190
- Taylor E. C., Knopf R. J., Borror A. L. Dimerization of 2-amino-5-nitrobenzonitrile. Journal of American Chemical Society 1960; 82: 3152–3157
- Tomita T., Sawamura F., Uetsuka R., Miura S., Tomita I., Inoue Y., Tsutsumi K. Antiatherogenic effects of a novel compound, NO-1886, in cholesterol-fed New Zealand White rabbits. Atherosclerosis 1994; 109(suppl.)69–70
- Tsuda Y., Tsuda Y. (Phosphonomethyl)benzamide derivatives. Chemical Abstracts 1987; 106: 67489s
- Tsutsumi K., Inoue Y., Shima A., Iwasaki K., Kawamura M., Murase T. The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. Journal of Clinical Investigation 1993; 92: 411–417
- Tsutsumi K., Inoue Y., Shima A., Murase T. Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats. Diabetes 1995; 44: 414–417
- Tsvetkov E. N., Malevannaya R. A., Lobanov D. I., Osipenko N. G., Kabachnik M. I. Electron effects of phosphorus-containing substituents. Induction constants of substituted phosphinyl groups. Zhurnal Obshchei Khimii 1969; 39: 2429–2433
- West K. M., Ahuja M. M. S., Bennett P. H., Czyzyk A., De Acosta O. M., Fuller J. H., Grab B., Grabauskas V., Jarrett R. J., Kosaka K., Keen H., Krolewski A. S., Miki E., Schliack V., Teuscher A., Watkins P. J., Stober J. A. The role of circulating glucose and triglyceride concentrations and their interactions with other ‘risk factors’; as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care 1983; 6: 361–369